Biocure Technology Inc. (CSE:CURE, OTCQB:BICTF) (the "Company" or "Biocure") BiocurePharm, Korea ("BPK"), a wholly owned subsidiary of Biocure Technology Inc. ("CURE") has entered into a collaboration agreement with Y Biologics ("YB"), a private R&D company in Korea who is specialized in antibody therapeutics in cancer, autoimmune disease and metabolic disease.
The post Biocure Signs a Collaboration Agreement with Y Biologics appeared first on Investing News Network.
Original Article: Biocure Signs a Collaboration Agreement with Y Biologics